Cell to Cure ApS: Financial statements 2023
CVR: 39401975
Source: annual report 2023, Danish Business Authority
01/09/2022 – 31/08/2023
Cell to Cure ApS (CVR 39401975) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 100,337 and a net result of DKK -1,533,822 compared with DKK -401,864 the year before. That is a decrease of 74.2% compared with the year before. Equity in the 2023 report amounted to DKK -1,899,371. The company had 5 employees in the financial year.
- Gross Profit
- DKK 100,337
- Profit/Loss
- DKK -1,533,822
- Equity
- DKK -1,899,371
- Total Assets
- DKK 1,871,398
- Employees
- 5
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 100 t. | -1.5 mio. | -1.9 mio. | 5 |
| 2022 | - | 389 t. | -402 t. | -366 t. | 5 |
| 2021 | - | 295 t. | 218 t. | 695 t. | 0 |
| 2020 | - | 523 t. | 405 t. | 462 t. | 0 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Cell to Cure ApS has published its annual report for 2022. Gross profit came to DKK 389,024, and the net result was DKK -401,864.
About Cell to Cure ApS
Cell to Cure ApS is a Danish company of the type Anpartsselskab based in Birkerød, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Cell2Cure ApS. The management consists of Jens Kastrup, Annette Ekblond and Mandana Haack-Sørensen. The board consists of Anders Østergaard (chair), Annette Ekblond, Jens Kastrup and Mandana Haack-Sørensen. The company's owners include MEDIC ADVICE ApS, Endeavour Cells ApS and Ekblond.ApS. The company has 5 employees (2026). In 2025, the company reported a gross profit of DKK -3,076,475 and a net result of DKK -9,792,604. Equity in the 2025 report amounted to DKK -1,179,103.